Post-earnings recap
Reported
Tue, Feb 1, 2011
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
Boston Scientific's strong EPS performance indicates better-than-expected profitability, which likely contributed to the stock's 2.15% increase. Investors may be encouraged by management's positive tone regarding product demand and market conditions. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.15 | N/A | +53.06% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a positive outlook on their product lines. They emphasized the importance of innovation and market responsiveness.
Management highlighted strong performance in key product areas.
They expressed confidence in ongoing market demand despite economic challenges.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—